Johnson & Johnson (VIE:JNJ)
Austria · Delayed Price · Currency is EUR | Market Cap | 460.78B +41.0% |
| Revenue (ttm) | 83.64B +7.9% |
| Net Income | 18.26B -3.5% |
| EPS | 7.50 -3.9% |
| Shares Out | n/a |
| PE Ratio | 25.23 |
| Forward PE | 18.68 |
| Dividend | 4.49 (2.34%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 124 |
| Open | 192.02 |
| Previous Close | 192.22 |
| Day's Range | 191.88 - 192.60 |
| 52-Week Range | 129.40 - 214.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson presents exploratory analyses from DAHLIAS study
Johnson & Johnson announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjogren’s disease showing that participants with ...
Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study
Johnson & Johnson announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 and continued to demonstrate sustained reduction in…
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies a...
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preservin...
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson...
Johnson & Johnson announces Phase 3 Proteus study met primary endpoints
Johnson & Johnson announced results from the final analysis of the Phase 3 Proteus study showing the investigational use of apalutamide plus hormone therapy, given for six months before and…
Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publica...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the ...
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk o...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypica...
Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study
Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival and overall survival ...
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second lin...
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today th...
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaq...
Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Management projects surpassing $100 billion in 2026 revenue, with accelerating growth driven by a robust pipeline in innovative medicines and MedTech. Oncology, cardiovascular, and surgical robotics are key growth drivers, while AI and drug-device synergies enhance R&D productivity. Portfolio reshaping and early-stage M&A support long-term ambitions.
Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launc...
Johnson & Johnson says nipocalimab approved in China
Johnson & Johnson's nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday.
Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026
The EP market is experiencing rapid growth, driven by AFib procedures, innovation, and global expansion, with strong leadership and a robust pipeline of new catheters and mapping technologies. The neurovascular franchise focuses on high-impact stroke solutions and less invasive treatments for chronic conditions.
Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, today announced that Johnson & Johnson has secured naming rig...
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managin...
Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026
The conference highlighted a robust R&D pipeline focused on oncology, immunology, and neuroscience, with recent advances in oral therapies and combination treatments. Regulatory and policy discussions centered on FDA leadership changes, evolving drug pricing models, and the growing impact of China on biopharma innovation.
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.